Educational attainment and response to HAART during initial therapy for HIV-1 infection
Identifieur interne : 000109 ( PascalFrancis/Curation ); précédent : 000108; suivant : 000110Educational attainment and response to HAART during initial therapy for HIV-1 infection
Auteurs : Linda G. Marc [États-Unis] ; Marcia A. Testa [États-Unis] ; Alexander M. Walker [États-Unis] ; Gregroy K. Robbins [États-Unis] ; Robert W. Shafer [États-Unis] ; Norman B. Anderson [États-Unis] ; Lisa F. Berkman [États-Unis]Source :
- Journal of psychosomatic research [ 0022-3999 ] ; 2007.
Descripteurs français
- Pascal (Inist)
- Niveau étude, Stress, Coping, Antirétroviral, Association médicamenteuse, Traitement, SIDA, Observance médicamenteuse, Efficacité personnelle, Virus immunodéficience humaine, Statut socioéconomique, Facteur prédictif, Etude multicentrique, International, Santé publique, Santé mentale, Environnement social, Homme, Antiviral, Pharmacothérapie.
- Wicri :
- topic : Santé publique, Santé mentale, Homme.
English descriptors
- KwdEn :
- AIDS, Antiretroviral agent, Antiviral, Coping, Drug combination, Drug compliance, Education level, Human, Human immunodeficiency virus, International, Mental health, Multicenter study, Pharmacotherapy, Predictive factor, Public health, Self efficacy, Social environment, Socioeconomic status, Stress, Treatment.
Abstract
Objective: Previous research has demonstrated an association between educational attainment (EA) and negative physical and psychological outcomes. This study investigated whether EA is associated with regimen failure during initial therapy with highly active antiretroviral treatment (HAART) and whether adherence self-efficacy (ASE), a coping resource, moderates the relationship between EA and regimen failure. Methods: A secondary analysis of AIDS Clinical Trial Group Protocol 384, an international, multi-center, randomized, partially double-blinded trial, included 799 male and 181 female antiretroviral-naïve subjects (age, 37.0±9.5 years). Participants were recruited from 1998 to 1999 and followed for a median of 2.3 years across 81 centers. The dependent variable was "time to first regimen failure." Covariates include baseline HIV-1 log10RNA and CD4+ counts, self-reported adherence, study site, ASE, age, sex, race, treatment assignment, and baseline use of nonantiretroviral medications. Results: ASE significantly moderated the relationship between EA and regimen failure. Results showed that for every 10-unit increase in ASE, individuals with "less than high school" education had a 17% reduction in regimen failure (hazard ratio=0.83; 95% confidence interval=0.70-0.98) when compared to the reference group "college/graduate," even after adjusting for baseline factors known to contribute to regimen failure. The time to first regimen failure was shorter with decreasing EA, trending toward significance (P=.08). Conclusions: There is a social gradient in HAART effectiveness, and ASE reduces the deleterious effects of lower EA on regimen failure. We recommend designing controlled interventions to evaluate the effectiveness of programs that increase ASE prior to initiation with HAART, particularly for those with lower EA.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000197
Links to Exploration step
Pascal:07-0489642Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Educational attainment and response to HAART during initial therapy for HIV-1 infection</title><author><name sortKey="Marc, Linda G" sort="Marc, Linda G" uniqKey="Marc L" first="Linda G." last="Marc">Linda G. Marc</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cornell HIV Clinical Trials Unit</s1><s2>New York, NY</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Psychiatry, Weill Medical College of Cornell</s1><s2>White Plains, NY</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Testa, Marcia A" sort="Testa, Marcia A" uniqKey="Testa M" first="Marcia A." last="Testa">Marcia A. Testa</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Walker, Alexander M" sort="Walker, Alexander M" uniqKey="Walker A" first="Alexander M." last="Walker">Alexander M. Walker</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Robbins, Gregroy K" sort="Robbins, Gregroy K" uniqKey="Robbins G" first="Gregroy K." last="Robbins">Gregroy K. Robbins</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Massachusetts General Hospital</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Shafer, Robert W" sort="Shafer, Robert W" uniqKey="Shafer R" first="Robert W." last="Shafer">Robert W. Shafer</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Stanford University Medical Center</s1><s2>Stanford, CA</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Anderson, Norman B" sort="Anderson, Norman B" uniqKey="Anderson N" first="Norman B." last="Anderson">Norman B. Anderson</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>American Psychological Association</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Berkman, Lisa F" sort="Berkman, Lisa F" uniqKey="Berkman L" first="Lisa F." last="Berkman">Lisa F. Berkman</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0489642</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0489642 INIST</idno><idno type="RBID">Pascal:07-0489642</idno><idno type="wicri:Area/PascalFrancis/Corpus">000197</idno><idno type="wicri:Area/PascalFrancis/Curation">000109</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Educational attainment and response to HAART during initial therapy for HIV-1 infection</title><author><name sortKey="Marc, Linda G" sort="Marc, Linda G" uniqKey="Marc L" first="Linda G." last="Marc">Linda G. Marc</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cornell HIV Clinical Trials Unit</s1><s2>New York, NY</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Psychiatry, Weill Medical College of Cornell</s1><s2>White Plains, NY</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Testa, Marcia A" sort="Testa, Marcia A" uniqKey="Testa M" first="Marcia A." last="Testa">Marcia A. Testa</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Walker, Alexander M" sort="Walker, Alexander M" uniqKey="Walker A" first="Alexander M." last="Walker">Alexander M. Walker</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Robbins, Gregroy K" sort="Robbins, Gregroy K" uniqKey="Robbins G" first="Gregroy K." last="Robbins">Gregroy K. Robbins</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Massachusetts General Hospital</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Shafer, Robert W" sort="Shafer, Robert W" uniqKey="Shafer R" first="Robert W." last="Shafer">Robert W. Shafer</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Stanford University Medical Center</s1><s2>Stanford, CA</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Anderson, Norman B" sort="Anderson, Norman B" uniqKey="Anderson N" first="Norman B." last="Anderson">Norman B. Anderson</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>American Psychological Association</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Berkman, Lisa F" sort="Berkman, Lisa F" uniqKey="Berkman L" first="Lisa F." last="Berkman">Lisa F. Berkman</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></analytic><series><title level="j" type="main">Journal of psychosomatic research</title><title level="j" type="abbreviated">J. psychosom. res.</title><idno type="ISSN">0022-3999</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of psychosomatic research</title><title level="j" type="abbreviated">J. psychosom. res.</title><idno type="ISSN">0022-3999</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Antiretroviral agent</term><term>Antiviral</term><term>Coping</term><term>Drug combination</term><term>Drug compliance</term><term>Education level</term><term>Human</term><term>Human immunodeficiency virus</term><term>International</term><term>Mental health</term><term>Multicenter study</term><term>Pharmacotherapy</term><term>Predictive factor</term><term>Public health</term><term>Self efficacy</term><term>Social environment</term><term>Socioeconomic status</term><term>Stress</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Niveau étude</term><term>Stress</term><term>Coping</term><term>Antirétroviral</term><term>Association médicamenteuse</term><term>Traitement</term><term>SIDA</term><term>Observance médicamenteuse</term><term>Efficacité personnelle</term><term>Virus immunodéficience humaine</term><term>Statut socioéconomique</term><term>Facteur prédictif</term><term>Etude multicentrique</term><term>International</term><term>Santé publique</term><term>Santé mentale</term><term>Environnement social</term><term>Homme</term><term>Antiviral</term><term>Pharmacothérapie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Santé publique</term><term>Santé mentale</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: Previous research has demonstrated an association between educational attainment (EA) and negative physical and psychological outcomes. This study investigated whether EA is associated with regimen failure during initial therapy with highly active antiretroviral treatment (HAART) and whether adherence self-efficacy (ASE), a coping resource, moderates the relationship between EA and regimen failure. Methods: A secondary analysis of AIDS Clinical Trial Group Protocol 384, an international, multi-center, randomized, partially double-blinded trial, included 799 male and 181 female antiretroviral-naïve subjects (age, 37.0±9.5 years). Participants were recruited from 1998 to 1999 and followed for a median of 2.3 years across 81 centers. The dependent variable was "time to first regimen failure." Covariates include baseline HIV-1 log<sub>10</sub>RNA and CD4<sup>+</sup> counts, self-reported adherence, study site, ASE, age, sex, race, treatment assignment, and baseline use of nonantiretroviral medications. Results: ASE significantly moderated the relationship between EA and regimen failure. Results showed that for every 10-unit increase in ASE, individuals with "less than high school" education had a 17% reduction in regimen failure (hazard ratio=0.83; 95% confidence interval=0.70-0.98) when compared to the reference group "college/graduate," even after adjusting for baseline factors known to contribute to regimen failure. The time to first regimen failure was shorter with decreasing EA, trending toward significance (P=.08). Conclusions: There is a social gradient in HAART effectiveness, and ASE reduces the deleterious effects of lower EA on regimen failure. We recommend designing controlled interventions to evaluate the effectiveness of programs that increase ASE prior to initiation with HAART, particularly for those with lower EA.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-3999</s0></fA01><fA02 i1="01"><s0>JPCRAT</s0></fA02><fA03 i2="1"><s0>J. psychosom. res.</s0></fA03><fA05><s2>63</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Educational attainment and response to HAART during initial therapy for HIV-1 infection</s1></fA08><fA11 i1="01" i2="1"><s1>MARC (Linda G.)</s1></fA11><fA11 i1="02" i2="1"><s1>TESTA (Marcia A.)</s1></fA11><fA11 i1="03" i2="1"><s1>WALKER (Alexander M.)</s1></fA11><fA11 i1="04" i2="1"><s1>ROBBINS (Gregroy K.)</s1></fA11><fA11 i1="05" i2="1"><s1>SHAFER (Robert W.)</s1></fA11><fA11 i1="06" i2="1"><s1>ANDERSON (Norman B.)</s1></fA11><fA11 i1="07" i2="1"><s1>BERKMAN (Lisa F.)</s1></fA11><fA14 i1="01"><s1>Cornell HIV Clinical Trials Unit</s1><s2>New York, NY</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Psychiatry, Weill Medical College of Cornell</s1><s2>White Plains, NY</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>Harvard School of Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="04"><s1>Massachusetts General Hospital</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Stanford University Medical Center</s1><s2>Stanford, CA</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>American Psychological Association</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>6 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>ACTG Data Analysis Concept Sheet Study Team</s1><s3>USA</s3></fA17><fA20><s1>207-216</s1></fA20><fA21><s1>2007</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>1382</s2><s5>354000161514340150</s5></fA43><fA44><s0>0000</s0><s1>© 2007 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>103 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>07-0489642</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of psychosomatic research</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Objective: Previous research has demonstrated an association between educational attainment (EA) and negative physical and psychological outcomes. This study investigated whether EA is associated with regimen failure during initial therapy with highly active antiretroviral treatment (HAART) and whether adherence self-efficacy (ASE), a coping resource, moderates the relationship between EA and regimen failure. Methods: A secondary analysis of AIDS Clinical Trial Group Protocol 384, an international, multi-center, randomized, partially double-blinded trial, included 799 male and 181 female antiretroviral-naïve subjects (age, 37.0±9.5 years). Participants were recruited from 1998 to 1999 and followed for a median of 2.3 years across 81 centers. The dependent variable was "time to first regimen failure." Covariates include baseline HIV-1 log<sub>10</sub>RNA and CD4<sup>+</sup> counts, self-reported adherence, study site, ASE, age, sex, race, treatment assignment, and baseline use of nonantiretroviral medications. Results: ASE significantly moderated the relationship between EA and regimen failure. Results showed that for every 10-unit increase in ASE, individuals with "less than high school" education had a 17% reduction in regimen failure (hazard ratio=0.83; 95% confidence interval=0.70-0.98) when compared to the reference group "college/graduate," even after adjusting for baseline factors known to contribute to regimen failure. The time to first regimen failure was shorter with decreasing EA, trending toward significance (P=.08). Conclusions: There is a social gradient in HAART effectiveness, and ASE reduces the deleterious effects of lower EA on regimen failure. We recommend designing controlled interventions to evaluate the effectiveness of programs that increase ASE prior to initiation with HAART, particularly for those with lower EA.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02S05</s0></fC02><fC02 i1="02" i2="X"><s0>002A26N03B</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Niveau étude</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Education level</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Nivel estudio</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Stress</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Stress</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Estrés</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Coping</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Coping</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Coronación</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Antirétroviral</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Antiretroviral agent</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Antiretroviral</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Association médicamenteuse</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Drug combination</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Asociación medicamentosa</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>SIDA</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>AIDS</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>SIDA</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Observance médicamenteuse</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Drug compliance</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Observancia de la medicación</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Efficacité personnelle</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Self efficacy</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Eficacia personal</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0><s2>NW</s2><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0><s2>NW</s2><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0><s2>NW</s2><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Statut socioéconomique</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Socioeconomic status</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Estatuto socioeconómico</s0><s5>11</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Facteur prédictif</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Predictive factor</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Factor predictivo</s0><s5>12</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Etude multicentrique</s0><s5>13</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Multicenter study</s0><s5>13</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Estudio multicéntrico</s0><s5>13</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>International</s0><s5>14</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>International</s0><s5>14</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Internacional</s0><s5>14</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Santé publique</s0><s5>15</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Public health</s0><s5>15</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Salud pública</s0><s5>15</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Santé mentale</s0><s5>16</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Mental health</s0><s5>16</s5></fC03><fC03 i1="16" i2="X" l="SPA"><s0>Salud mental</s0><s5>16</s5></fC03><fC03 i1="17" i2="X" l="FRE"><s0>Environnement social</s0><s5>17</s5></fC03><fC03 i1="17" i2="X" l="ENG"><s0>Social environment</s0><s5>17</s5></fC03><fC03 i1="17" i2="X" l="SPA"><s0>Contexto social</s0><s5>17</s5></fC03><fC03 i1="18" i2="X" l="FRE"><s0>Homme</s0><s5>18</s5></fC03><fC03 i1="18" i2="X" l="ENG"><s0>Human</s0><s5>18</s5></fC03><fC03 i1="18" i2="X" l="SPA"><s0>Hombre</s0><s5>18</s5></fC03><fC03 i1="19" i2="X" l="FRE"><s0>Antiviral</s0><s5>31</s5></fC03><fC03 i1="19" i2="X" l="ENG"><s0>Antiviral</s0><s5>31</s5></fC03><fC03 i1="19" i2="X" l="SPA"><s0>Antiviral</s0><s5>31</s5></fC03><fC03 i1="20" i2="X" l="FRE"><s0>Pharmacothérapie</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="20" i2="X" l="ENG"><s0>Pharmacotherapy</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="20" i2="X" l="SPA"><s0>Farmacoterapia</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Facteur sociodémographique</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Sociodemographic factor</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Factor sociodemográfico</s0><s5>37</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Immunodéficit</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Immune deficiency</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Inmunodeficiencia</s0><s5>38</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Immunopathologie</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Immunopathology</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Inmunopatología</s0><s5>40</s5></fC07><fN21><s1>323</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000109 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000109 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:07-0489642
|texte= Educational attainment and response to HAART during initial therapy for HIV-1 infection
}}
| This area was generated with Dilib version V0.6.33. |  |